title: Gemcitabine and Chlorotoxin Conjugated Iron Oxide Nanoparticles for Glioblastoma Therapy.
abstract: Many small-molecule anti-cancer drugs have short blood half-lives and toxicity issues due to non-specificity. Nanotechnology has shown great promise in addressing these issues. Here, we report the development of an anti-cancer drug gemcitabine-conjugated iron oxide nanoparticle for glioblastoma therapy. A glioblastoma targeting peptide, chlorotoxin, was attached after drug conjugation. The nanoparticle has a small size (~32 nm) and uniform size distribution (PDI ≈ 0.1), and is stable in biological medium. The nanoparticle effectively enter cancer cells without losing potency compared to free drug. Significantly, the nanoparticle showed a prolonged blood half-life and the ability to cross the blood-brain barrier in wild type mice.
authors.affiliation: Department of Materials Science and Engineering, University of Washington, Seattle, Washington, 98195, USA; Clinical Research Division, Fred Hutchinson Cancer Research Centre, Seattle, Washington, 98109, USA.
authors.forename: Qingxin
authors.initials: Q
authors.lastname: Mu
authors.affiliation: Department of Bioengineering, University of Washington, Seattle, Washington, 98195, USA.
authors.forename: Guanyou
authors.initials: G
authors.lastname: Lin
authors.affiliation: Department of Chemical Engineering, University of Washington, Seattle, Washington, 98195, USA.
authors.forename: Victoria K
authors.initials: VK
authors.lastname: Patton
authors.affiliation: Department of Materials Science and Engineering, University of Washington, Seattle, Washington, 98195, USA.
authors.forename: Kui
authors.initials: K
authors.lastname: Wang
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Centre, Seattle, Washington, 98109, USA.
authors.forename: Oliver W
authors.initials: OW
authors.lastname: Press
authors.affiliation: Department of Materials Science and Engineering, University of Washington, Seattle, Washington, 98195, USA.
authors.forename: Miqin
authors.initials: M
authors.lastname: Zhang
references.citation: Cancer Res. 2009 Aug 1;69(15):6200-7
references.pmid: 19638572
references.citation: Curr Opin Oncol. 2001 Nov;13(6):514-21
references.pmid: 11673693
references.citation: N Engl J Med. 2008 Jul 31;359(5):492-507
references.pmid: 18669428
references.citation: Biochim Biophys Acta. 2013 May;1828(5):1396-404
references.pmid: 23384419
references.citation: Drug Metab Dispos. 1992 Nov-Dec;20(6):849-55
references.pmid: 1362937
references.citation: Brain Res. 2009 Mar 19;1261:91-9
references.pmid: 19401168
references.citation: Ann Oncol. 2006 May;17 Suppl 5:v188-94
references.pmid: 16807454
references.citation: Eur J Cancer. 2011 Jan;47(2):230-8
references.pmid: 20943374
references.citation: Oncology. 2001;60(1):8-18
references.pmid: 11150902
references.citation: Mol Oncol. 2012 Apr;6(2):155-76
references.pmid: 22440008
references.citation: ACS Nano. 2010 Aug 24;4(8):4587-94
references.pmid: 20731441
references.citation: ACS Nano. 2014 Oct 28;8(10):10383-95
references.pmid: 25247850
references.citation: Cancer Cell. 2014 Apr 14;25(4):516-29
references.pmid: 24684846
references.citation: Langmuir. 2008 Jul 15;24(14):7512-9
references.pmid: 18540685
references.citation: Oncology. 2003;64(3):191-206
references.pmid: 12697958
references.citation: Cancer Chemother Pharmacol. 2010 Jan;65(2):391-7
references.pmid: 19847425
references.citation: Adv Drug Deliv Rev. 2008 Aug 17;60(11):1252-1265
references.pmid: 18558452
references.citation: Adv Drug Deliv Rev. 2004 Sep 22;56(11):1649-59
references.pmid: 15350294
references.citation: Nanomedicine. 2011 Dec;7(6):859-70
references.pmid: 21550422
references.citation: Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):612-20
references.pmid: 17255284
references.citation: Cancer Res. 2010 Nov 15;70(22):9243-52
references.pmid: 20935218
references.citation: Science. 2004 Mar 19;303(5665):1818-22
references.pmid: 15031496
references.citation: J Biol Chem. 2003 Feb 7;278(6):4135-44
references.pmid: 12454020
references.citation: Nanomedicine (Lond). 2010 Nov;5(9):1357-69
references.pmid: 21128719
references.citation: J Control Release. 1998 Apr 30;53(1-3):93-103
references.pmid: 9741917
references.citation: J Am Chem Soc. 2004 Jun 16;126(23):7206-11
references.pmid: 15186157
references.citation: BJU Int. 2012 Feb;109(4):496-505
references.pmid: 22313502
references.citation: Nanomedicine. 2011 Dec;7(6):841-9
references.pmid: 21419876
references.citation: Nat Rev Drug Discov. 2010 Aug;9(8):615-27
references.pmid: 20616808
references.citation: Small. 2009 Jul;5(14):1637-41
references.pmid: 19334014
references.citation: Drugs. 1997 Sep;54(3):447-72
references.pmid: 9279506
references.citation: Int J Pharm. 2011 May 16;409(1-2):278-88
references.pmid: 21371545
references.citation: Nanoscale. 2012 Nov 21;4(22):7012-20
references.pmid: 23041969
references.citation: Biomaterials. 2015 Apr;46:1-12
references.pmid: 25678111